This book highlights the use of artificial intelligence (AI), big data and precision oncology for medical decision making in cancer screening, diagnosis, prognosis and treatment. Precision oncology has long been thought of as ideal for the management and treatment of cancer. This strategy promises to revolutionize the treatment, control, and prevention of cancer by tailoring tests, treatments and predictions to specific individuals or population groups. In order to accomplish these goals, vast amounts of patient or population group specific data needs to be integrated and analysed to be able to identify key patterns or features which can be used to define or characterize the disease or the response to the disease in these individuals. These patterns or features can be as varied as molecular patterns or features in medical images. This level of data analysis and integration can only be achieved through the use of AI.

The book is divided into three parts starting with a section on the use of artificial intelligence for screening, diagnosis and monitoring in precision oncology. The second part: Artificial intelligence and Omics in precision oncology, highlights the use of AI and epigenetics, metabolomics, microbiomics in precision oncology. The third part covers artificial intelligence in cancer therapy and its clinical applications. It also highlights the use of AI tools for risk prediction, early detection, diagnosis and accurate prognosis.

This book, written by experts in the field from academia and industry, will appeal to cancer researchers, clinical oncologists, pathologists, medical students, academic teaching staff and medical residents interested in cancer research as well as those specialising as clinical oncologists.


Les mer
<p>This book highlights the use of artificial intelligence (AI), big data and precision oncology for medical decision making in cancer screening, diagnosis, prognosis and treatment.</p>
Chapter 1. Introduction: The Application of AI in Precision Oncology: Tailoring Diagnosis, Treatment, and the Monitoring of Disease Progression to the Patient.- Part I. Artificial Intelligence for Screening, Diagnosis, Monitoring in Precision Oncology.- Chapter 2. Application of AI in Novel Biomarkers Detection that Induce Drug Resistance, Enhance Treatment Regimens and Advancing Precision Oncology.- Chapter 3. Use of Artificial Intelligence in Implementing Mainstream Precision Medicine to Improve Traditional Symptom-driven Practice of Medicine: Allowing Early Interventions and Tailoring better-personalized Cancer Treatments.- Chapter 4. AI as a Novel Approach for Exploring ccfNAs in Personalized Clinical Diagnosis and Prognosis: Providing Insight into the Decision-Making in Precision Oncology.- Chapter 5. AI-Enhanced Digital Pathology and Radiogenomics in Precision Oncology.- Part II. Artificial Intelligence and Omics in Precision Oncology.- Chapter 6. Epigenetics Analysis Using Artificial Intelligence in the Era of Precision Oncology.- Chapter 7. Association of Metabolomics with AI in Precision Oncology: Emerging Perspectives for More Effective Cancer Care.- Chapter 8. Artificial Intelligence Application to Microbiomics Data for Improved Clinical Decision Making in Precision Oncology.- Part III. Artificial Intelligence in Cancer Therapy and the Clinical Applications.- Chapter 9. AI and Nanotechnology in Realizing the Goal of Precision Medicine: Tailoring the Best Treatment for Personalized Cancer Treatment.- Chapter 10. Artificial Intelligence-Based Medical Devices Revolution in Cancer Screening: Impact into Clinical Practice.- Chapter 11. Intelligent Drug Design and Use for Cancer Treatment: The Roles of AI and Precision Oncology in Targeting Patient-Specific Splicing Profiles.- Chapter 12. Applying Artificial Intelligence Prediction Tools for Advancing Precision Oncology in Immunotherapy: Future Perspectives in Personalized Care.- Chapter 13. Employing AI-Powered Decision Support Systems in Recommending the Most Effective Therapeutic Approaches for Individual Cancer Patients: Maximizing Therapeutic Efficacy.- Chapter 14. AI-Pathway Companion in Clinical Decision Support: Enabling Personalized and Standardized Care Along Care Pathways in Oncology.- Chapter 15. AI Tools Offering Cancer Clinical Applications for Risk Predictor, Early Detection, Diagnosis, and Accurate Prognosis: Perspectives in Personalised Care.- Chapter 16. Conclusion and Insights into the Future of AI in Precision Oncology.
Les mer
This book highlights the use of artificial intelligence (AI), big data and precision oncology for medical decision making in cancer screening, diagnosis, prognosis and treatment. Precision oncology has long been thought of as ideal for the management and treatment of cancer. This strategy promises to revolutionize the treatment, control, and prevention of cancer by tailoring tests, treatments and predictions to specific individuals or population groups. In order to accomplish these goals, vast amounts of patient or population group specific data needs to be integrated and analysed to be able to identify key patterns or features which can be used to define or characterize the disease or the response to the disease in these individuals. These patterns or features can be as varied as molecular patterns or features in medical images. This level of data analysis and integration can only be achieved through the use of AI.

The book is divided into three parts starting with a section on theuse of artificial intelligence for screening, diagnosis and monitoring in precision oncology. The second part: Artificial intelligence and Omics in precision oncology, highlights the use of AI and epigenetics, metabolomics, microbiomics in precision oncology. The third part covers artificial intelligence in cancer therapy and its clinical applications. It also highlights the use of AI tools for risk prediction, early detection, diagnosis and accurate prognosis.

This book, written by experts in the field from academia and industry, will appeal to cancer researchers, clinical oncologists, pathologists, medical students, academic teaching staff and medical residents interested in cancer research as well as those specialising as clinical oncologists.


Les mer
Discusses AI and precision oncology in individualized screening, diagnosis, therapy and monitoring of cancer patients Highlights the use of AI in radiomics, microbiomics, metabolomics and nanotechnology in precision oncology Focusses on AI’s ability to predict outcomes, decide on and monitor treatment and progression
Les mer
GPSR Compliance The European Union's (EU) General Product Safety Regulation (GPSR) is a set of rules that requires consumer products to be safe and our obligations to ensure this. If you have any concerns about our products you can contact us on ProductSafety@springernature.com. In case Publisher is established outside the EU, the EU authorized representative is: Springer Nature Customer Service Center GmbH Europaplatz 3 69115 Heidelberg, Germany ProductSafety@springernature.com
Les mer

Produktdetaljer

ISBN
9783031215087
Publisert
2024-01-22
Utgiver
Vendor
Springer International Publishing AG
Høyde
235 mm
Bredde
155 mm
Aldersnivå
Research, P, 06
Språk
Product language
Engelsk
Format
Product format
Heftet

Redaktør

Biografisk notat

Zodwa Dlamini is a Professor of Molecular Oncology and the founding Director and the Executive Head of the Pan African Cancer Research Institute (PACRI) in South Africa. She is the Director of South African Medical Research Council (SAMRC) Precision Oncology Research Unit (PORU). She is the DSI/NRF SARChI Chair in Precision Oncology and Cancer Prevention (POCP). She is a member of the American Association for Cancer Research (AACR) Advisory Group on Sub-Saharan Africa. She is a member of the AACR Pathology Resources in Africa Advisory Group. Professor Dlamini is a member of the African Organisation for Research and Training in Cancer (AORTIC) Research Committee Scientific Advisory Board. She is an elected member of the Academy of Science of South Africa. Professor Dlamini is an overseas Fellow of the Royal Society of Medicine (London). She is the Associate Editor for Frontiers in Oncology: Cancer Genetics Section.